Sign in

NCT06710587Not yet recruiting

Does Use of the Voy Program Improve Weight Loss Percentage and Other Health Outcomes in a Population Already Taking GLP/GIP-1RA Medication?

A Decentralised Open Label Trial to eValuate the Efficacy Of the VoY Program in A Patient Population Using GLP/GIP-1RA thERapy

Source: ClinicalTrials.gov · Last updated 29 Nov 2024 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

The aim of the trial is to assess the impact of the Voy Program on weight loss and other health outcomes in an obese population already approved for GLP/GIP-1RA medication. If an eligible participant consents to take part in the trial, they will be randomly allocated into one of the two trial groups. One group will continue with the standard pathway for GLP/GIP-1RA as part of their usual care for weight loss, while the other group will utilise the Voy Program in addition to the standard pathway. In the intervention group, the Voy Program will include personalised sessions with a qualified coach as well as access to resources including managing nutrition and movement. The frequency of the coaching sessions will be led by the participant but will normally start fortnightly. All participants will be enrolled in the trial for 12 months and will be asked to complete questionnaires on a monthly and quarterly basis.

Status (registry)
Not yet recruiting
Study type
Interventional
Enrollment
470 (estimated)
First submitted
22 Nov 2024
Start date
2 Jan 2025
Primary completion date
2 Apr 2026
Lead sponsor
Menwell Limited
Diseases
Obesity
NCT number
NCT06710587

What you commit to

  • Study type: Interventional
  • Planned participants: 470
  • From 2 Jan 2025 to the primary completion date, 2 Apr 2026
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Previous surgery or endoscopic intervention for obesity, or planned surgery or endoscopic intervention for obesity in the next 12 months.
  • Currently using other weight loss medications, or use of other weight loss medications in the past 6 months.
  • Currently using medications that cause weight gain, including systemic steroids, or used such medications in the past 6 months.
  • Participation in another interventional clinical study or use of investigational drugs in the last 6 months.

Other illness

  • Known diabetes mellitus (Type 1 or 2) or thyroid disease.
  • Severe eating disorder (Binge eating scale ≥27).
  • Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial.

Other

  • Pregnant or breastfeeding women, or those planning to get pregnant in the next 12 months.
  • Lost ≥ 5kg in the last 3 months intentionally or otherwise.
  • Severe anxiety or depression (either PHQ-9 \>15 or GAD7 \>10).

Who the study is looking for

  • Aged 18-65.
  • BMI≥30,
    • Or BMI≥27 with any of the following comorbidities as diagnosed by a Doctor:
    • High blood pressure
    • High cholesterol
    • Obstructive sleep apnoea
    • Erectile dysfunction
    • Asthma
    • Osteoarthritis
    • Chronic back pain
    • PCOS
    • Fatty liver disease
  • Approved for the standard GLP/GIP-1RA pathway by Voy as part of usual care for weight loss.
  • People who use either an iOS or Android smartphone using operating system iOS 16 or Android 8 or later.
  • Agree to not use another intervention for weight loss for the duration of the trial.
    • Other diet specific interventions such as meal replacement shakes.
    • Over the counter medication / supplements such as appetite suppressants, thermogenics, herbal supplements.
    • Any other medicated weight loss program.
    • Structured weight loss programs such as Weight Watchers, Noom, Second Nature.
    • Non-surgical medical weight management such as lipotropic injections and metabolic enhancers.
    • Surgical interventions such as a gastric bypass, banding, or other bariatric surgery
    • Other personalised nutrition programmes, such as ZOE
  • Able and willing to provide Informed Consent and adhere to trial procedures.

Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.